- Home
- Multiple Myeloma
- Discover the Science
- Efficacy
- LTFU Data
-
Safety
- Boxed WARNING
- Warnings and Precautions
- Common Adverse Reactions
- MajesTEC-1 Longer-Term Follow-Up Safety Analysis at 23 Months
- Cytokine Release Syndrome
- Neurotoxicity
- Specific Populations
- Dosing and Administration
- Support and Resources
- For APPs and Nurses